

JUL 1 7 2002

্র্র TECH CENTER 1600/2900

Application No.: 09/458299

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

Ø	<ol> <li>This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.</li> </ol>
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other: SPP ENLLOSED NOTE
Аp	plicant Must Provide:
	An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An $\underline{\text{initial}}$ or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
M	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For For	Rules Interpretation, call (703) 308-4216 CRF Submission Help. call (703) 308-4212

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE





Koort Green Sollie Goward I Krosser Jong A Goldsten Robert W Esmond Tacy Gene S Durlin Michael B Ray Robert E Soucht Erik K Steffe Michael Q Lee Erik K Steffe Michael Q Lee Linda E Albong Lawrence B Bugarky Donald J Featherston Michael W Messinger Judith U. Km.
Timothy J. Shea. Ir
Pamid E. Garrett
Jeffery T. Hethers
Hedi L. Kraus.
Copital D. Sayles.
Edward W. Yee
Albert L. Ferro?
Oonald R. Banowit
Peter A. Jackman
Molfy A. McCall
Teresa U. Medler
J. Fersulo III.
Eldova Ellison Floyd
W. Russell Swindell
W. Russell Swindell
W. Russell Swindell

Thomas C Fiala Brian I Dei Buono Virgil Lee Beaston' Reginald D Lucas Kimberh N Reddick Theodore A. Wood Elizabeth I Haanes Brice E Chalker Joseph S Ostroff Frank R Cottonphant' Christine M Lhuler Rea Lynn Prengaman' Jane Shershenonich' Lawrence I Carroll' George S Bardmesser

Registered Patent Age Karen R Markown. 2 Andrea J Kamage Nancy J Leth Noseh M Conrad III Ann E Summerheid Heiene C Carbon Gaby L Longsworth Marthew J Dowd Auron L Schwartz Angefique G Uy Bors A Marvenko Mary B Tung Kattma Y Pe Bryan L Sketton Jason D Enenberg

私 マクラハウ

Settion Counsel Samuel L. Fox Renneth C. Bass In Lind A. Dunner

\*Admitted only in Marylan.
\* Admitted only in Virginia
\* Admitted only in Texas
\*Practice Limited to
Federal Agencies

July 12, 2002

## **RECEIVED**

WRITER'S DIRECT NUMBER: (202) 371-2641 INTERNET ADDRESS: HCARLSON@SKGE COM

JUL 1 7 2002

Commissioner for Patents Washington, D.C. 20231

## **TECH CENTER 1600/2900**

Re: U.S. Utility Patent Application

Appl. No. 09/458,299; Filed: December 10, 1999

For: Inducing Cellular Immune Responses to HER2/neu Using Peptide
And Nucleic Acid Compositions

Inventors: FIKES et al.

Our Ref: 2060.0140000/EKS/HCC

Art Unit: 1644

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Fee Transmittal Form (PTO/SB/17);
- 2. Petition For Extension of Time Under 37 C.F.R. § 1.136(a)(1);
- 3. Change of Correspondence Address;
- 4. A copy of the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures;
- 5. Amendment and Submission of Substitute Sequence Listing Under 37 C.F.R. § 1.825(a);
- 6. Substitute page 99 of the specification;
- 7. A computer readable copy of the sequence listing;
- 8. <u>955</u> pages of a paper copy of a sequence listing:

Commissioner for Patents July 12, 2002 Page 2

- 9. Our check no. <u>35840</u> for \$<u>400.00</u> to cover the two month extension of time fee; and
- 10. One return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Helene C. Carlson Agent for Applicants Registration No. 47,473

EKS/HCC/eaf Enclosures SKGE DC1:33829.1

PTO SB 17 (10-01)

Approved for use through 10:31 2002 OMB 0651-0032

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

OIPE JO	FEE TRANSMITTAL for FY 2002
JUL 1 5 5005	IOI FY 2002

ent fees are subject to annual revision.

TOTAL AMOUNT OF THE THE

(\$)400.00

Сотр	olete if Known
Application Number	09/458,299
Filing Date	December 10, 1999
First Named Inventor	FIKES et al.
Examiner Name	Schwadron, R.B.
Group Art Unit	1644
Attorney Docket No.	2060.0140000/EKS/HCC

METHOD OF PAYMENT (check one)				FEI	E CALCULATION (continued)	
The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to:	3. ADDI Large	TIONAL Entity		Entity	Surcharge - late filing fee or oath Surcharge - late provisional filing fee or cover to Non-English specification  For filing a request for exparte reevamination	Ç
Deposit Account Number 19-0036	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Feepald
Deposit Account Name Sterne, Kessler, Goldstein & Fox P.L.t. C.	105	130	205	65	Surcharge - late filing fee or oath	8
☑ Charge Any Additional Fee Required	127	50	227	25	Surcharge - late provisional filing fee or cover	1
Under 37 CFR §§ 1.16 and 1.17	139	130	139	130	Non-English specification	
Applicant claims small entity status Sec 37 CFR 1.27	147	2,520	147	2,520	For filing a request for ex parte reexamination	
	112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
2. Payment Enclosed:	113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
Check Credit card Money Order Other* Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 19-0036	115	110	215	55	Extension for reply within first month	
FEE CALCULATION	116	400	216	200	Extension for reply within second month	\$400.00
1. BASIC FILING FEE	117	920	217	<b>4</b> 60	Extension for reply within third month	
Large Entity Small Entity	118	1,440	218	720	Extension for reply within fourth month	
Fee Fee Fee Fee Description Fee Paid Code (\$) Code (\$)	128	1,960	228	980	Extension for reply within fifth month	<del>                                     </del>
101 740 201 370 Utility filing fee	119	320	219	160	Notice of Appeal	
106 330 206 165 Design filing fee	120	320	220	160	Filing a brief in support of an appeal	
107 510 207 255 Plant filing fee	121	280	221	140	Request for oral hearing	
108 740 208 370 Reissue filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding	
114 160 214 80 Provisional filing fee	140	110	240	55	Petition to revive - unavoidable	<del>                                     </del>
CLIDTOTAL (1) (C) O	141	1,280	241	640	Petition to revive - unintentional	
SUBTOTAL (1) (S) 0	142	1,280	242	<b>64</b> 0	Utility issue fee (or reissue)	
	143	460	243	230	Design issue fee	
	144	620	244	310	Plant issue fee	
	122	130	122	130	Petitions to the Commissioner	
2. EXTRA CLAIM FEES Fee from Extra below Fee Paid	123	•30	.53	130	Petitions related to provisional applications	
Total Claims 20** = X =	126	.80	•26	180	Submission of Information Disclosure Stmt	
Indep Claims 3** = X = =	581	40	481	40	Recording each patent assignment per property (times number of properties)	
Multiple Dependent =	146	740	246	370	Filing a submission after final rejection (37 CFR 1 129(a))	
Large Entity Small Entity Fee Fee Fee Fee Fee Description Code (\$) Code (\$)	149	740	249	370	For each additional invention to be examined (37 CFR 1.129(b))	
103 18 203 9 Claims in excess of 20	179	740	279	370	Request for Continued Examination (RCE)	
102 84 202 42 Independent claims in excess of 3	169	900	169	900	Request for expedited examination of a	<u> </u>
104 280 2'04 140 Multiple dependent claim	la				design application	
108 84 209 42 **Reissue independent claims over original patient	Other fee (s	specify)				1

SUBMITTED BY				Complete (if applicable)		
Name (Print/Type)	rrelepe C. Carislin	Registrati in No.	47,473	Telephone	202-371-2600	
Signature	, ,			Date		